SOLTA MEDICAL INC|4Jan 27, 8:29 PM ET

SOLTA MEDICAL INC 4

4 · SOLTA MEDICAL INC · Filed Jan 27, 2014

Form 4

Period: 2014-01-23

Vice President of Global Sales

Transactions

Disposition to Issuer
Common Stock
2014-01-23$2.92/sh−41,378$120,824→ 0 total
Exercise/Conversion
Performance Restricted Stock Unit
2014-01-23−5,963→ 0 total
Exp: 2023-02-04→ Common Stock (5,963 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.55/sh−20,000$31,000→ 0 total
Exercise: $1.37Exp: 2018-12-31→ Common Stock (20,000 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$1.41/sh−2,000$2,820→ 0 total
Exercise: $1.51Exp: 2019-07-31→ Common Stock (2,000 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$0.15/sh−50,000$7,500→ 0 total
Exercise: $2.77Exp: 2022-12-11→ Common Stock (50,000 underlying)
Exercise/Conversion
Common Stock
2014-01-23+5,963→ 5,963 total
Disposition to Issuer
Common Stock
2014-01-23$2.92/sh−5,963$17,412→ 0 total
Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$0.17/sh−3,000$510→ 0 total
Exercise: $2.75Exp: 2021-01-31→ Common Stock (3,000 underlying)
Disposition to Issuer
Employee Stock Option (Right to Buy)
2014-01-23$0.36/sh−2,500$900→ 0 total
Exercise: $2.56Exp: 2023-01-31→ Common Stock (2,500 underlying)

Footnotes (3)

[F1]Disposed of pursuant to the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger"), at the merger consideration of $2.92 per share (the "Merger Consideration"). Includes 28,166 shares deemed acquired pursuant to the grant of restricted stock units ("RSU s") on various dates. The vesting of the RSU's was accelerated in connection with the Merger.
[F2]Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.
[F3]This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment equal to the product of (a) the number of shares underlying this option and (b) the difference between the Merger Consideration and the exercise price per share of this option.

Documents

1 file